Hydroxychloroquine
CAT:
804-HY-W031727-04
Size:
250 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Hydroxychloroquine
- CAS Number: 118-42-3
- UNSPSC Description: Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling[1][2][3][4][5][6][7][8].
- Target Antigen: Autophagy; Parasite; SARS-CoV; Toll-like Receptor (TLR)
- Type: Reference compound
- Related Pathways: Anti-infection;Autophagy;Immunology/Inflammation
- Applications: COVID-19-anti-virus
- Field of Research: Cancer; Infection
- Assay Protocol: https://www.medchemexpress.com/hydroxychloroquine.html
- Purity: 99.77
- Solubility: DMSO : ≥ 100 mg/mL
- Smiles: ClC1=CC=C2C(NC(CCCN(CCO)CC)C)=CC=NC2=C1
- Molecular Weight: 335.87
- References & Citations: [1]Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.|[2]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40.|[3]Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237.|[4]Persoons L, et al. Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. Antiviral Res. 2021;193:105127. |[5]Ramser B, et al. Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol. 2009;129(10):2419-2426. |[6]Ruiz A, et al. Effect of hydroxychloroquine and characterization of autophagy in a mouse model of endometriosis. Cell Death Dis. 2016;7(1):e2059. Published 2016 Jan 14. |[7]Edwards MH, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96(12):4380-4384.|[8]Gómez-Guzmán M, et al. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2014;64(2):330-337. ACS Omega. 2024 Feb 28;9(10):11870-11882.|Acta Pharmacol Sin. 2021 Feb 19.|Aging. 2021 Mar 10;13(6):8421-8439.|Am J Cancer Res. 2020 Nov 1;10(11):3896-3910.|Arthritis Rheumatol. 2022 Sep 3.|Autophagy. 2021 Sep 15;1-19.|Autophagy. 2022 Aug 29.|Autophagy. 2022 Jan 6;1-20.|Biochem Biophys Res Commun. 2 March 2022.|Biochem Biophys Res Commun. 2020 Dec 10;533(3):474-480.|Bioorg Chem. 2024 Apr 29:147:107412.|Br J Pharmacol. 2023 Feb 14.|Cell Biochem Funct. 2022 Apr 29.|Curr Med. 2023 Oct 17.|iScience. 30 June 2022, 104690.|J Exp Pharmacol. 2022 Nov 8;14:353-365|J Transl Med. 2024 Aug 22;22(1):785.|Mol Cancer. 2024 Oct 31;23(1):243.|Nat Biotechnol. 2022 Dec;40(12):1834-1844.|Nat Commun. 2022 Jun 14;13(1):3419.|Patent. US20230218606A1.|Patent. US20240238271A1.|Phytomedicine. 2024 Sep 26:135:156059.|Res Sq. 2024 Jun 21.|Research Square Preprint. 2023 Sep 6.|Virology. 2023 Jul 24.|ACS Appl Mater Interfaces. 2022 Oct 27.|Acta Pharm Sin B. 2021 Dec;11(12):3966-3982.|Acta Pharmacol Sin. 2022 Oct 25.|Autophagy. 2022 Oct 27.|Biochem Pharmacol. 2021 Dec 28;114904.|bioRxiv. 2024 Dec 5:2024.12.04.626665.|BMC Med. 2021 Oct 15;19(1):247.|Cell Death Dis. 2020 Apr 24;11(4):279.|Cell Discov. 2020 Mar 18;6:16.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Cell Signal. 2019 Feb;54:17-26. |Clin Chem. 2019 Dec;65(12):1522-1531. |Clin Sci (Lond). 2019 Aug 14;133(15):1759-1777.|Eur J Pharmacol. 2 September 2022, 175237.|Front Bioeng Biotechnol. 2020 May 8;8:378.|Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.|Heliyon. 2023 Oct 31.|iScience. 30 June 2022, 104690.|J Autoimmun. 2019 May;99:39-47.|J Biol Chem. 2023 May 11;104814.|J Control Release. 2020 Jan 28;320:304-313.|Life Sci. 2020 Apr 1;246:117366.|Life Sci. 2020 Feb 15;243:117277.|Life Sci. 2021 Oct 26;120095.|Nat Biomed Eng. 2021 Nov 8.|Nat Commun. 2021 Aug 16;12(1):4964.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Pharmacol Res. 2021 Apr 30;169:105642.|Phytomedicine. 2021, 153465.|Research Square Preprint. 2021 Oct.|Sci Rep. 2022 Oct 29;12(1):18259.|STAR Protoc. 2022, 3(4): 101859.|Theranostics. 2020 Apr 27;10(13):5829-5844.
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: Launched